Hanmi Pharmaceutical is developing a rare disease treatment aimed at the global market and is conducting phase 2 clinical trials in Korea. With HM15912 as a candidate for the treatment of Short bowel syndrome (SBS), clinical trials will be conducted at Samsung Medical Center.

The MFDS approved Hanmi's phase 2 clinical plan for HM15912 on the 8th. This is a phase 2 clinical trial (DOLPHINS-2) to evaluate the safety, pharmacokinetics and pharmacokinetics of HM15912 in adult subjects with SBS-IF. A total of seven patients will participate in this test, of which two are domestic. Short bowl syndrome (SBS) is a disease in which the small intestine is naturally short in length or more than 60% of the small in